New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 11, 2014
14:56 EDTCEMPCempra to present data on solithromycin at ECCMID
Cempra announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, in Barcelona, Spain, that continue to enhance the profile of solithromycin in regards to potential new indications, safety and spectrum of activity particularly against contemporary strains. Presentations will occur on Saturday, May 10 to Tuesday, May 13.Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra said, "We continue to collect exciting data on the emerging profile of solithromycin, our fourth-generation macrolide. The data presented at this year's ECCMID are excellent examples of that trend. Proof of concept in otitis media was presented and this adds to the broadening use potential of solithromycin that includes pediatric use, infections in pregnancy, gonorrhea and non-infectious diseases such as COPD and NASH among others. We also presented the full hepatic insufficiency study that we announced in 3Q13, which demonstrated the benign tolerability profile seen to date. The emerging safety profile is promising based on this study as well as the safety profile seen in our Phase 2 CABP trial and the lack of a QT effect in our Thorough QT study."
News For CEMP From The Last 14 Days
Check below for free stories on CEMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
13:15 EDTCEMPCempra management to meet with Jefferies
Meetings to be held in Austin/Dallas/San Antonio on September 23-24 hosted by Jefferies.
September 9, 2014
08:10 EDTCEMPCempra receives $10M milestone payment from Toyama Chemical
Cempra (CEMP) announced the receipt of a $10M milestone payment from Toyama Chemical, a subsidiary of FUJIFILM Holdings (FUJIY), triggered by Toyama's progress of its solithromycin clinical development program in Japan, the world's second largest antibiotic market. The payment was made following Toyama's receipt of regulatory clearance to begin a Phase 2 trial of solithromycin in Japan following successful completion of a Phase 1 study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use